Tag Archives: T2D

August, 2018

April, 2018

December, 2017

October, 2017

  • 23 October

    FDA Approves New Once-Weekly Bydureon BCise Injectable Medicine for Type 2 Diabetes

    WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BYDUREON® BCise™ (exenatide extended-release) injectable suspension, a new formulation of BYDUREON® (exenatide extended-release) injectable suspension in an improved once-weekly, single-dose autoinjector device for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines …

July, 2017

June, 2017

April, 2017

January, 2017